

Bone&JointScience

Our Innovation in Focus

LEGION[◇] Primary Knee System for total knee arthroplasty: Design rationale and early results

John Watson¹, Jason Jordan BSME²

¹ Smith & Nephew, Inc., Baar, Switzerland

² Smith & Nephew, Inc., Memphis, TN, USA

1 Research goal

To describe the design modifications to an established device in the creation of the LEGION[◇] Primary Knee System, together with its early clinical results.

2 Type of evidence



Design rationale



Pre-clinical study



Clinical study



Economic analysis



Registry data



Literature review


Figure 1a–c: Design features of the LEGION PS/CR (pictured) that differ from GENESIS II.



a. Medial posterior condyle thickness (mm):
 Sizes 1–6: LEGION CR/PS (9.5);
 [GENESIS II CR/PS (7)]
 Sizes 7–8: LEGION CR/PS (11.5);
 [GENESIS II CR/PS (9)]



b. Femoral augmentation LEGION CR/PS: Threaded screw augments. [GENESIS II CR/PS: Cemented augments]



c. PS box differences
 PS box wall height (mm):
 LEGION PS (17.1–20.5);
 [GENESIS II PS (13.8–18.0)]
 PS anterior wall:
 LEGION PS (Yes);
 [GENESIS II PS (No)]

3 Clinical relevance

- The GENESIS II Total Knee System was introduced in 1995 and has resulted in limited revisions,¹ with one recent study showing an excellent survivorship of 98.1% at a follow-up time of 15 years.²
- Complex knee disorders (e.g., varus/valgus deformities) present orthopedic surgeons with unique challenges during primary total knee arthroplasty (TKA), and often require devices that provide substantial intraoperative flexibility.³
- LEGION builds on the foundation of GENESIS II, with specific design changes that accommodate a wide variety of patient anatomies through surgeon-directed external rotation, the ability to add femoral augmentation, and easy intraoperative transition to a revision system when necessary.

4 Key result

- The cruciate-retaining (CR) and posterior-stabilized (PS) designs of GENESIS II and LEGION are identical, with the exception of three differences (Figure 1a–c, see page 3 for a full comparison with LEGION).
- These design differences are not expected to affect tibio-femoral wear performance, as both devices have comparable mean cumulative volumetric wear rates after approximately 5 million cycles of knee simulator testing.^{4,5}
- Two-year results from a prospective, multicenter study of LEGION indicate that only two patients (1.4%) out of 138 underwent revision (one for infection and one for patella clunk, at 2.3 and 18.2 months, respectively).

5 Important considerations

- Further follow-up will be needed to determine the mid- and long-term performance of this device.

Background

The GENESIS[®] II system was developed in 1995 for primary TKA, and has several key design features, including:


- An S-shaped trochlear groove – simulates a natural femur in its movement of the patella from a lateral position in extension to midline in flexion, thereby reducing lateral release rates to approximately 3%⁶ compared with approximately 14%⁷ for competitive devices;
- A bone-conserving PS box cut – removes less bone than several competitive systems⁸ and leaves the critical anterior bone bridge intact;
- An asymmetric baseplate shape that matches the tibial anatomy⁹ – reduces rate and severity of malrotation¹⁰
- VERILAST[®] Technology (introduced in 2008) – exhibits significantly less wear when compared with a cobalt-chromium/ultra-high-molecular weight polyethylene bearing¹¹ and incorporates OXINIUM[®] (oxidized zirconium alloy), a material that unlike cobalt-chromium has <0.0035% nickel, <0.002% cobalt, and <0.02% chromium content,¹² and highly cross-linked polyethylene (XLPE).

GENESIS II has produced positive clinical results over the last two decades (**Figure 2**). A 2012 systematic analysis collected data from 11 clinical studies (1,201 knees in total) with this device; 14 revisions were identified, resulting in a 96.0% implant survivorship rate at a maximum follow-up of 11.9 years.¹ One recent study with the longest-yes follow-up for GENESIS II (15 years) reported an excellent survivorship of 98.1%. This was a single-surgeon study in which the choice for a CR or PS implant was made after assessment of deformity and ligament status, and both cemented and uncemented femoral fixation were used.²

GENESIS II has proven successful in conventional TKA for standard indications; however, surgeons also perform TKAs in patients whose cases can be considered relatively complex, such as those with extra-articular deformities, posttraumatic arthrosis, and neuropathic arthritis.³ For such demanding cases it is necessary to customize TKA device component choice, positioning, and technique in order to achieve optimal postsurgical results.³

The LEGION[®] Primary Knee was introduced in 2005 (originally under the name GENESIS[®] II SPC), and later became part of the LEGION Total Knee System, which also includes LEGION Revision and LEGION Hinge Knees. LEGION builds on the design foundation of GENESIS II, with specific changes to accommodate a wide variety of patient anatomies. This analysis provides an overview of these design changes, as well as the early results from a prospective, multicenter study with LEGION.

Figure 2: Kaplan-Meier implant survivorship estimates for GENESIS II at final assessment in eight studies (991 knees) with ≥5 years follow up.^{2,6,13-18}



*Indicates a study in which Kaplan-Meier survivorship estimates were reported. Other studies had survival extrapolated from revision information (e.g., lack of revisions = 100% survival).

H 95% confidence interval (with exception of Bourne¹³, which reports standard deviation)

Methods


Design background

- LEGION® is a total knee system, with options in both CR and PS designs, as well as constrained and hinged knee components.
- LEGION CR and PS have designs similar to GENESIS II CR and PS, with three differences shown in **Figure 3a-c**.

Wear analyses (AMTI 6-station knee simulator)

- First analysis: wear of LEGION CR 7.5 Mrad XLPE tibial inserts articulating against GENESIS II CR OXINIUM® femoral components was measured. The test was conducted for 5.19 million cycles.⁵
- Second analysis: the wear of LEGION CR 7.5 Mrad XLPE tibial inserts articulating against LEGION CR OXINIUM femoral components was measured. The test was conducted for 45 million cycles, with wear assessed at 5.19 million cycles.⁴

Figures 3a-c: Design features of the LEGION CR/PS that differ from GENESIS II CR/PS.



Prospective study

- A prospective study was initiated across five institutions in the United States, in which 138 patients (**Table 1**) received LEGION® Primary and were followed for two years.
- One patient died and seven were terminated early due to other reasons.

Results

Design changes


- GENESIS® II employs built-in 3° external rotation useful for the basic surgeries needed for most primary TKAs. LEGION does not incorporate built-in external rotation. Instead, the surgeon externally rotates the femoral component to match the patient's anatomy (**Figure 4a-b**). This is achieved by the posterior-medial condyle being the same thickness as the posterior-lateral condyle
- Both GENESIS II and LEGION employ the same instrumentation with the exception of the rotation of the sizing guide
- Design changes provide for more seamless intraoperative transition to revision TKA if necessary. This is because all versions of the LEGION Knee utilize the same articulating geometry, femoral cuts, and A/P box, making the need for additional bone resection unnecessary
- Ream-through femoral trials that allow the surgeon to move easily from a CR to PS design, as well as locate the correct medial/lateral position for the PS box
- Only one design change involves an articulating surface (**Figure 3a**). Both GENESIS II and LEGION have a tibiofemoral conformity ratio of 1:1.05 in the coronal plane and the same kinematic contact throughout the range of motion in the sagittal plane. This would explain the comparable results of the wear analysis below. The patellofemoral articular surfaces are identical between GENESIS II and LEGION femorals.

Table 1 Patient demographics (n=138)*

Gender, patients (%)	
Male	49 (35.5)
Female	89 (64.5)
Age, years (range)	66.4 (24-88)
Height, centimeters (range)	167.3 (144.7-193.0)
Weight, kilograms (range)	87.2 (43.1-128.8)
Body mass index, kg/m² (range)	31.1 (17.4-51.9)

*All variables except gender presented as means.

Figure 4a-b: Femoral rotation, as evidenced from placement of cutting block (a) to ultimate implantation (b).



Wear analysis

- Separate analyses^{4,5} revealed comparable wear between the LEGION[®] CR and GENESIS[®] II CR (**Table 2**).

Table 2 Results of separate wear analyses at 5.19 million cycles (AMTI 6-station knee simulator).


Articulating components	Mean cumulative volumetric wear ± SD
LEGION CR 7.5 Mrad XLPE tibial inserts against GENESIS II CR OXINIUM femoral components ⁵	2.51 ± 1.93 mm ³
LEGION CR 7.5 Mrad XLPE tibial inserts against LEGION CR OXINIUM femoral components	2.67 ± 1.20 mm ³

SD = standard deviation; XLPE = crosslinked polyethylene.

Prospective study

- At two years follow up, there were two revisions noted in 138 patients (1.4%; **Figure 5**)

Figure 5: Revisions reported in prospective study.



Conclusions

LEGION[®] builds upon the well-established GENESIS[®] II designs, which have achieved excellent survivorship of 98.1% at 15 years follow up.² LEGION and GENESIS II achieve equivalent articulation but do so via different surgical approaches to femoral external rotation. GENESIS II offers built-in external rotation by having asymmetric posterior condyles, whereas LEGION allows surgeon-directed external rotation with symmetric posterior condyles. The differing techniques are used with the same tibial implants for both systems and produce comparable implant tibio-femoral kinematics and wear performance after approximately 5 million cycles of knee simulator testing. Based on laboratory wear simulation testing at 45 million cycles,¹¹ the LEGION Primary CR Knee System with VERILAST[®] Technology completed 45 million cycles of in vitro simulated wear testing, which is an estimate of 30 years of activity.* Other LEGION design modifications provide surgeons with a more seamless system during surgery, allowing the ability to convert from CR to PS, from PS to constrained, and from primary to revision TKA, as well as the ability to use any tibial insert variant without having to remove the femoral component, all using a common instrument system. Early clinical results with LEGION indicate that it has an acceptable revision rate at two years; however, additional follow-up is needed to gauge whether these results will continue in the medium to long-term.

* The results of in-vitro wear simulation testing have not been proven to quantitatively predict clinical wear performance. Also, a reduction in total polyethylene wear volume or wear rate alone may not result in improved clinical outcomes as wear particle size and morphology are also critical factors in the evaluation of the potential for wear mediated osteolysis and associated aseptic implant loosening. Particle size and morphology were not evaluated as part of the testing.

References

1. **Bhandari M, Pascale W, Sprague S, Pascale V.** The Genesis II in primary total knee replacement: a systematic literature review of clinical outcomes. *Knee.* 2012;19(1):8-13.
2. **Victor J, Ghijssels S, Tajdar F, et al.** Total knee arthroplasty at 15-17 years: does implant design affect outcome? *Int Orthop.* 2014;38(2):235-241.
3. **Lonner JH, Booth Jr. RE.** Total knee arthroplasty in outliers. In: Barrack RL, Booth Jr RE, Lonner JH, McCarthy JC, Mont MA, Rubash HE, eds. *Orthopaedic Knowledge Updated: Hip and knee reconstruction.* 3rd ed. Rosemont, IL: American Academy of Orthopaedic Surgeons; 2006:111-121.
4. Smith & Nephew internal report. OR-09-177. December 2009.
5. Smith & Nephew internal report. OR-10-128. September 2010.
6. **Laskin RS, Davis J.** Total knee replacement using the Genesis II prosthesis: a 5-year follow up study of the first 100 consecutive cases. *Knee.* 2005;12(3):163-167.
7. **Yang CC, McFadden LA, Dennis DA, Kim RH, Sharma A.** Lateral retinacular release rates in mobile- versus fixed-bearing TKA. *Clin Orthop Relat Res.* 2008;466(11):2656-2661.
8. **Haas SB, Nelson CL, Laskin R.** Posterior stabilized knee arthroplasty: an assessment of bone resection. *Knee.* 2000;7:25-29.
9. **Westrich GH, Agulnik MA, Laskin RS, Haas SB, Sculco TP.** Current analysis of tibial coverage in total knee arthroplasty. *Knee.* 1997:87-91.
10. **Martin S, Saurez A, Ismaily S, Ashfaq K, Noble P, Incavo SJ.** Maximizing tibial coverage is detrimental to proper rotational alignment. *Clin Orthop Relat Res.* 2014;472(1):121-125.
11. **Papannagari R, Hines G, Sprague J, Morrison M.** Long-term wear performance of an advanced bearing knee technology. ISTA; Oct 6-9, 2010; Dubai, UAE.
12. ASTM International Standard Specification for Wrought Zirconium-2.5Niobium Alloy for Surgical Implant Applications (UNS R60901) Designation: F 2384 – 05 and Standard Specification for Cobalt-28 Chromium-6 Molybdenum Alloy Castings and Casting Alloy for Surgical Implants (UNS R30075): Designation: F 75 – 07.
13. **Bourne RB, Laskin RS, Guerin JS.** Ten-year results of the first 100 Genesis II total knee replacement procedures. *Orthopedics.* 2007;30(8 Suppl):83-85.
14. **Endres S.** High-flexion versus conventional total knee arthroplasty: a 5-year study. *J Orthop Surgery (Hong Kong).* 2011;19(2):226-229.
15. **Harato K, Bourne RB, Victor J, Snyder M, Hart J, Ries MD.** Midterm comparison of posterior cruciate-retaining versus -substituting total knee arthroplasty using the Genesis II prosthesis. A multicenter prospective randomized clinical trial. *Knee.* 2008;15(3):217-221.
16. **Kim YH, Park JW, Kim JS.** Comparison of the Genesis II total knee replacement with oxidised zirconium and cobalt-chromium femoral components in the same patients: a prospective, double-blind, randomised controlled study. *J Bone Joint Surgery Br.* 2012;94(9):1221-1227.
17. **Park DH, Leong J, Palmer SJ.** Total knee arthroplasty with an oxidised zirconium femoral component: a 5-year follow-up study. *J Orthop Surg (Hong Kong).* 2014;22(1):75-79.
18. **Victor J, Banks S, Bellemans J.** Kinematics of posterior cruciate ligament-retaining and -substituting total knee arthroplasty: a prospective randomised outcome study. *J Bone Joint Surg Br.* 2005;87(5):646-655.

° Trademark of Smith & Nephew.
Registered US Patent and Trademark Office All Trademarks acknowledged.

Disclaimer Great care has been taken to maintain the accuracy of the information contained in the publication. However, neither Smith & Nephew, nor the authors can be held responsible for errors or any consequences arising from the use of the information contained in this publication. The statements or opinions contained in editorials and articles in this journal are solely those of the authors thereof and not of Smith & Nephew. The products, procedures, and therapies described are only to be applied by certified and trained medical professionals in environments specially designed for such procedures. No suggested test or procedure should be carried out unless, in the reader's professional judgment, its risk is justified. Because of rapid advances in the medical sciences, we recommend that independent verification of diagnosis, drugs dosages, and operating methods should be made before any action is taken. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer. Some of the products, names, instruments, treatments, logos, designs, etc. referred to in this journal are also protected by patents and trademarks or by other intellectual property protection laws even though specific reference to this fact is not always made in the text. Therefore, the appearance of a name, instrument, etc. without designation as proprietary is not to be construed as a representation by the publisher that it is in the public domain. This publication, including all parts thereof, is legally protected by copyright. Any use, exploitation or commercialization outside the narrow limits of copyrights legislation, without the publisher's consent, is illegal and liable to prosecution. This applies in particular to photostat reproduction, copying, scanning or duplication of any kind, translating, preparation of microfilms and electronic data processing and storage. Institutions' subscriptions allow to reproduce tables of content or prepare lists of articles including abstracts for internal circulation within the institutions concerned. Permission of the publisher is required for resale or distribution outside the institutions. Permission of the publisher is required for all other derivative works, including compilations and translations. Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. For inquiries contact the publisher at the address indicated.



Lit no: 03386 V1 04/15

Produced and published by the Scientific & Medical Affairs Department,
Smith & Nephew Orthopaedics AG.

Published Apr 2015

Copyright © 2015 by Smith & Nephew

Smith & Nephew Orthopaedics AG, Oberneuhofstrasse 10d, 6340 Baar,
Switzerland

◊Trademark of Smith & Nephew. Registered US Patent and Trademark Office.
All Trademarks acknowledged.

Bone&JointScience is available on Smith & Nephew's Education and
Evidence website, www.smith-nephew.com/education